Xarelto (rivaroxaban) / J&J 
Welcome,         Profile    Billing    Logout  
 97 Diseases   247 Trials   247 Trials   14602 News 


«12...127128129130131132133134135136137...170171»
  • ||||||||||  rivaroxaban / Generic mfg.
    Clinical, Journal:  Optimal Rivaroxaban Dose in Asian Patients With Atrial Fibrillation and Normal or Mildly Impaired Renal Function. (Pubmed Central) -  Jan 10, 2020   
    Conclusions- Among Asians with atrial fibrillation and CrCl ≥50 mL/min, both R20 and R15 were associated with reduced risk of ischemic stroke, intracranial hemorrhage, major bleeding, and all-cause death without significantly increased risk of gastrointestinal bleeding compared with warfarin. In patients with CrCl ≥50 mL/min, on-label R20 showed better results for the composite clinical outcome compared with off-label R15.
  • ||||||||||  Journal:  European Stroke Organisation Guideline on Reversal of Oral Anticoagulants in Acute Intracerebral Haemorrhage. (Pubmed Central) -  Jan 8, 2020   
    The aim of the present European Stroke Organisation guideline document is to provide clinically useful evidence-based recommendation on reversal of anticoagulant activity VKA (warfarin, phenprocoumon and acenocoumarol), direct factor II (thrombin) inhibitors (dabigatran etexilat) and factor-Xa-inhibitors (apixaban, edoxaban and rivaroxaban) in patients with acute intracerebral haemorrhage...Overall, we strongly recommend using prothrombin complex over no treatment and fresh-frozen plasma in patients on VKA plus vitamin K. We further strongly recommend using idarucizumab in patients on dabigatran and make a recommendation for andexanet alfa in patients on rivaroxaban and apixaban over no treatment...We recommend against using tranexamic acid and rFVIIa, outside of trials. The presented treatment recommendations aim to normalise coagulation, there is no or only indirect data on effects on functional outcome or mortality, and only little data from randomised controlled trials.
  • ||||||||||  rivaroxaban / Generic mfg., warfarin / Generic mfg.
    A rare case of abdominal pain:related to idiopathic left ovarian vein thrombosis (Carpenter Hall) -  Jan 4, 2020 - Abstract #WSMRF2020WSMRF_323;    
    Historically, heparin followed by bridging to warfarin until a therapeutic INR is achieved was the main stay of treatment. Recently, direct oral anticoagulants offers a potentially useful alternative even the efficacy of these drugs has not been studied yet.
  • ||||||||||  enoxaparin sodium / Generic mfg.
    Journal:  Effect of an activated charcoal product (DOAC Stop™) intended for extracting DOACs on various other APTT-prolonging anticoagulants. (Pubmed Central) -  Jan 1, 2020   
    It also bound the intravenous anticoagulants argatroban and lepirudin, but it had no effect on heparin, enoxaparin or danaparoid in plasma...Conclusions The AC-based product extracted DOACs efficiently with no effect on heparin-type anticoagulants. It did bind argatroban and hirudin-type anticoagulants, which might occur in plasmas from some inpatients, and APTT results obtained after its use should be interpreted after due consideration of patient medications.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, warfarin / Generic mfg.
    Clinical, Journal:  How to maintain an adherence to oral anticoagulant in a patient with atrial fibrillation? (Pubmed Central) -  Dec 26, 2019   
    For elderly and old patients with AF and numerous comorbidities, the proposal of a simpler pharmacotherapy regimen is especially important. In a number of large modern studies performed in clinical practice, high adherence to rivaroxaban therapy has been established, which may be a result of taking this DOA 1 time per day, its safety and effectiveness.
  • ||||||||||  fluorouracil / Generic mfg.
    Clinical, Journal:  A Case Report of Luminal A Male Inflammatory Breast Cancer that Was Difficult to Treat Because of Trousseau Syndrome (Pubmed Central) -  Dec 26, 2019   
    The condition of the disease was stabilized by FEC (5-FU, epirubicin, cyclophosphamide) therapy, but it became difficult to secure the blood vessel...This case of inflammatory luminal in male breast cancer that caused thrombus was difficult to treat. Thrombosis in advanced cancer patients is often pointed out, but since male breast cancer patients tend to take a long time to visit the hospital after becoming aware of the mass and arrive at an advanced state, it is necessary to notify the public of the existence of male breast cancer.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J
    Retrospective data, Review, Journal:  Rivaroxaban for cancer-associated venous thromboembolism: A systematic review and meta-analysis protocol. (Pubmed Central) -  Dec 26, 2019   
    Thrombosis in advanced cancer patients is often pointed out, but since male breast cancer patients tend to take a long time to visit the hospital after becoming aware of the mass and arrive at an advanced state, it is necessary to notify the public of the existence of male breast cancer. Our study aims to estimate the efficacy and safety of rivaroxaban for patients with cancer-associated VTE and to provide recommendations to key stakeholders.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J
    Journal:  Rivaroxaban for Left Ventricular Thrombus. (Pubmed Central) -  Dec 24, 2019   
    Assessment of trough rivaroxaban concentration with LC-MS/MS or anti-Xa, but not with APTT or PT, may help to identify patients at increased risk of bleeding. No abstract available
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, aspirin / Generic mfg.
    Journal, Combination therapy:  Nox2-mediated platelet activation by glycoprotein (GP) VI: effect of rivaroxaban alone and in combination with aspirin. (Pubmed Central) -  Dec 23, 2019   
    In platelets co-incubated with ASA, rivaroxaban amplified the ASA antiplatelet effect, which was achieved with 30 ng/ml and prevalently attributable to Nox2 inhibition and impaired isoprostane biosynthesis. Here we show that rivaroxaban, at concentrations achievable in human circulation, inhibits PA via GPVI interaction and eventually Nox2-mediated isoprostanes biosynthesis and amplifies the ASA antiplatelet effect.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J
    Journal:  Venous thromboembolic complications following surgical treatment for degenerative spinal disease. (Pubmed Central) -  Dec 23, 2019   
    VTEs are an uncommon but potentially lethal complication in patients who undergo surgery for a degenerative spinal disease. Incidence and mortality were low in a consecutive cohort where rivaroxaban was used as thrombosis prophylaxis in patients with an increased preoperative risk of VTE.
  • ||||||||||  Clinical, Review, Journal:  Reversal of oral anticoagulation in patients with acute intracerebral hemorrhage. (Pubmed Central) -  Dec 23, 2019   
    A variety of pharmacological alternatives to vitamin K antagonists (VKA) have emerged over recent years (direct oral anticoagulants, DOAC, i.e., dabigatran, rivaroxaban, apixaban, and edoxaban) which show a reduced risk for the occurrence of intracerebral hemorrhage (ICH)...While the management of VKA-ICH is mainly based on the immediate reversal of elevated levels of international normalized ratio using prothrombin complex concentrates, hemostatic management of DOAC-associated ICH is challenging requiring specific antidotes, notably idarucizumab and andexanet alfa. This review will provide an overview of the latest studies and trials on hemostatic reversal agents and timing and summarizes the effects on hemorrhage progression and clinical outcomes in patients with OAC-ICH.